488
0 Kommentare
Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden - Seite 4
About Novartis
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments
in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 1
billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125,000 people of more than 140 nationalities work at Novartis around the world. Find out
more at www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com
References
[1] An Integral Measure of Serial Neurofilament Light Chain Assessments in Blood is a Predictor of Long-Term Disability Progression in Relapsing-Remitting Multiple Sclerosis. J. Kuhle et.
al.
[2] Neurofilament Light Levels in the Blood of Patients with Secondary Progressive MS are higher than in Primary Progressive MS and may Predict Brain Atrophy in both MS Subtypes. J. Kuhle, et.
al.
[3] Neurofilament Light Chain is a Useful Biomarker in Paediatric Multiple Sclerosis. M. C. Reinert, et. al.
[4] Longer-Term Safety with Siponimod Treatment in Multiple Sclerosis: Pooled Analysis of Data from the BOLD and EXPAND Trials and their Extensions, L. Kappos, et. al
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com
Eric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com |
Angela Fiorin Novartis Global Pharma Communications +41 61 324 8631 (direct) +41 79 752 6955 (mobile) angela.fiorin@novartis.com |
Lesen Sie auch
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
Central | North America | ||
Samir Shah | +41 61 324 7944 | Richard Pulik | +1 212 830 2448 |
Pierre-Michel Bringer | +41 61 324 1065 | Cory Twining | +1 212 830 2417 |
Thomas Hungerbuehler | +41 61 324 8425 | ||
Isabella Zinck | +41 61 324 7188 |